The first cvs drug that was licensed for the treatment of sore throat has been cleared by the Food and Drug Administration (FDA).
The company has been selling the drug, called CVS-10, since 2010.
But it was not approved by the FDA for use in the US because the company had not met the company’s own criteria for a clinical trial.
The FDA’s new approval came after it looked at more than 1.3 million patient records.
It is the first clinical trial in the world to be approved by both the FDA and the European Medicines Agency (EMA), which regulates the development and marketing of medicines in Europe.
CVS-XR was approved by EMA for use to treat sore throat, an allergy, and nasal congestion, according to a statement from the company.
It has not yet been approved by other countries, according the company, but will be in clinical trials in those countries in 2018.
The company said in a statement that it is working to get the drug approved by US regulators, but did not say when that might be.
“We are grateful to the FDA, the EMA, and our collaborators for allowing us to take this important step in addressing the needs of people with sore throat,” CVS spokesperson John Waddell said.
“Our goal is to be ready for the US market by the end of 2018.”
According to the company in its statement, there is a limited number of patients in the United States who require the drug.
Dr Matthew Bower, an allergist at Memorial Sloan Kettering, said it would be “a big relief” if the drug is approved.
“[The drug] is very good, but the biggest benefit is it has been proven safe,” he said.
According a company statement, the new approval comes after the FDA took several months to conduct the first large-scale clinical trial of the drug in the UK.
In May 2018, the company applied to the EEMA for a Phase 2 clinical trial to test the drug’s safety in people with asthma.
Since then, it has tested its drug on 7,500 people.
On Wednesday, CVS reported earnings that beat analysts’ expectations.
For the full year, the stock had a loss of $1.15 per share, which was about the same as Wall Street expectations.